| A Trial of SHR6508 in Secondary Hyperparathyroidism (NCT05221008) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2022-03-10 |
| A Study to Assess the Efficacy and Safety of Paricalcitol in the Treatment of Chronic Kidney Disease With Secondary Hyperparathyroidism (NCT04994080) | Chengdu Suncadia Medicine Co., Ltd. | 2022-02-01 |
| Injection of Teriparatide to Prevent Hypocalcemia After Parathyroidectomy in Dialysis Patients (TeriCa). (NCT04750460) | Saint Petersburg State University, Russia | 2021-03-01 |
| Changes in Cardiac Functions in Patients Treated With Parathyroidectomy for Secondary Hyperparathyroidism (NCT06187480) | Mersin University | 2021-01-01 |
| Impact of Parathyroidectomy on Cardiovascular Calcification in Dialysis-dependent Patients (NCT03937349) | Saint Petersburg State University, Russia | 2019-05-14 |
| A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis (NCT03633708) | Amgen | 2019-04-29 |
| Study of KHK7580 in Subjects With Secondary Hyperparathyroidism in Asia (NCT03822507) | Kyowa Kirin Co., Ltd. | 2019-04-09 |
| Phase 3 Study of SK-1403 (NCT03801980) | Sanwa Kagaku Kenkyusho Co., Ltd. | 2019-01-21 |
| SK-1403 Long-term Treatment Study; Long-term Study in Patients With Secondary Hyperparathyroidism Receiving Hemodialysis (NCT03626948) | Sanwa Kagaku Kenkyusho Co., Ltd. | 2018-09-13 |
| Pharmacokinetics and Safety Study of CTAP101 Capsules in Japanese and Non-Japanese Healthy Subjects and Non-Japanese Healthy Subjects (NCT03660800) | OPKO Health, Inc. | 2018-08-20 |
| Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) (NCT03299244) | Amgen | 2018-05-15 |
| The Longitudinal PTH-Study (NCT03464149) | Medical University of Vienna | 2018-03-20 |
| A Phase 1 Study to Evaluate PK, Safety and Tolerability of AMG 416 (NCT03283098) | Amgen | 2018-03-01 |
| Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients (NCT03182699) | Rainer Oberbauer | 2017-10-01 |
| IOPTH Usefulness for Predicting Successful Surgery in Secondary Hyperparathyroidism (NCT04484116) | Hospital General Ajusco Medio | 2017-07-01 |
| Dose Adjustment Trial of SK-1403 in Hemodialysis Patients With Secondary Hyperparathyroidism (NCT03226171) | Sanwa Kagaku Kenkyusho Co., Ltd. | 2017-06-20 |
| the Study on Prognostic for Hemodialysis Patients (NCT03194087) | Beijing Friendship Hospital | 2017-01-01 |
| Pathogenesis of Compromised Bone Quality and Mechanics in Chronic Kidney Disease (NCT03626246) | Columbia University | 2016-07-01 |
| Phase 3 Study of KHK7580 (NCT02549417) | Kyowa Kirin Co., Ltd. | 2015-09-29 |
| Comparison of Total Parathyroidectomy With and Without Autotransplantation (NCT02536287) | The Second Hospital of Anhui Medical University | 2015-09-01 |
| Phase 3 Study of KHK7580 (NCT02549391) | Kyowa Kirin Co., Ltd. | 2015-09-01 |
| The Effect of Diuretics on Mineral and Bone Disorder in Chronic Kidney Disease Patients (NCT03082742) | University of Sao Paulo General Hospital | 2015-08-01 |
| Cinacalcet in Management of Secondary Hyperparathyroidism in Haemodialysis Patients (NCT02338934) | Penang Hospital, Malaysia | 2015-01-01 |
| The Efficacy and Safety of Microwave Ablation for Mild-to-moderate Secondary Hyperparathyroidism Patients Undergoing Hemodialysis (NCT02332135) | Wenhu Liu | 2015-01-01 |
| Phase 2 Study of KHK7580 (NCT02216656) | Kyowa Kirin Co., Ltd. | 2014-07-01 |
| Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis (NCT02143271) | Kyowa Kirin Co., Ltd. | 2014-05-01 |
| A Study to Evaluate the Effect of ASP7991 in Secondary Hyperparathyroidism Patients Undergoing Hemodialysis (NCT02133404) | Astellas Pharma Inc | 2014-03-14 |
| Prevalence of Secondary Hyperparathyroidism Among Patients With Diabetic Nephropathy (NCT03137316) | Benha University | 2014-01-01 |
| Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet (NCT01896232) | Amgen | 2013-08-13 |
| Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol (NCT01725113) | Winthrop University Hospital | 2012-11-01 |
| A Phase 2A Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism (NCT01653379) | Deltanoid Pharmaceuticals | 2012-08-01 |
| Open-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-4169) in Patients With Secondary Hyperparathyroidism (NCT01576146) | KAI Pharmaceuticals | 2012-03-01 |
| Etelcalcetide to Treat Secondary Hyperparathyroidism in Hemodialysis Patients With Chronic Kidney Disease-Mineral and Bone Disorder (NCT01414114) | KAI Pharmaceuticals | 2011-12-05 |
| A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis (NCT01382212) | AbbVie (prior sponsor, Abbott) | 2011-10-01 |
| Effects of Vitamin D on Renal Blood Flow, Proteinuria and Inflammation in Patients With Chronic Kidney Disease (NCT01426724) | University of Virginia | 2011-09-01 |
| Intravenous Paricalcitol in Chronic Hemodialysis Patients (NCT03023748) | The University of Hong Kong | 2011-09-01 |
| Quality of Life in Greek Hemodialysis Patients Receiving Zemplar Intravenous (NCT01368042) | AbbVie (prior sponsor, Abbott) | 2011-08-01 |
| Efficacy and Safety of High Intensity Focused Ultrasound (HIFU) Device to Treat Secondary Hyperparathyroidism (NCT01421407) | Theraclion | 2011-08-01 |
| A Study to Follow-up Patients With End Stage Renal Disease Undergoing Hemodialysis, Receiving Selective Vitamin D Receptor Activator's for Prevention and Treatment of Secondary Hyperparathyroidism (NCT01149291) | AbbVie (prior sponsor, Abbott) | 2011-07-01 |
| Pediatric Chronic Kidney Disease Safety and Efficacy (NCT01277510) | Amgen | 2011-06-28 |
| Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism (NCT01341782) | AbbVie (prior sponsor, Abbott) | 2011-05-01 |
| Safety, Tolerability and Efficacy of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism (NCT01254565) | KAI Pharmaceuticals | 2011-02-20 |
| Study to Assess Patient Management Practices and Quality of Life With Paricalcitol Capsules in the Treatment of Secondary Hyperparathyroidism in Stage 3-5 Chronic Kidney Disease Patients Not Yet on Dialysis (NCT01265992) | AbbVie (prior sponsor, Abbott) | 2011-02-01 |
| Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease (NCT01290029) | Amgen | 2011-01-25 |
| Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT) (NCT01219855) | OPKO Health, Inc. | 2010-10-01 |
| Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH Level (NCT01101113) | Seoul National University Hospital | 2010-09-01 |
| Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to 16 With Chronic Kidney Disease Stage 5 Receiving Peritoneal Dialysis Within Current Clinical Practice (NCT01134315) | AbbVie (prior sponsor, Abbott) | 2010-06-01 |
| LEO 27847 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Secondary Hyperparathyroidism Patients (NCT01167309) | LEO Pharma | 2010-06-01 |
| Cinacalcet Versus Parathyroidectomy in Peritoneal Dialysis Patients (NCT01447368) | The University of Hong Kong | 2010-05-10 |
| Cinacalcet in Paediatric Secondary Hyperparathyroidism (SHPT) Due to Chronic Kidney Disease (CKD) (NCT01479088) | ENRICO VERRINA | 2010-03-01 |
| Trial to Optimize Mineral Outcomes in Dialysis Patients (NCT01100723) | University of Colorado, Denver | 2010-03-01 |
| Parathyroidectomy vs Cinacalcet in the Treatment of Secondary Hyperparathyroidism Post Renal Transplantation (NCT01178450) | Josep M Cruzado | 2010-01-01 |
| Vitamin D Status in Males in Jerusalem Area and Its Correlation to Parathyroid Hormone (PTH) Level and Bone Mineral Density (NCT01025128) | Clalit Health Services | 2010-01-01 |
| Effect of Vitamin D Supplement on Inflammation Markers in High-Risk Cardiovascular Patients With Chronic Kidney Disease (NCT01012414) | Thomas Jefferson University | 2010-01-01 |
| Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D (NCT00977080) | Abbott | 2009-11-01 |
| FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease (NCT00999037) | University of California, Los Angeles | 2009-10-01 |
| Paricalcitol Compared to Maxacalcitol in Chronic Kidney Disease Patients With Secondary Hyperparathyroidism (NCT00990704) | Abbott | 2009-10-01 |
| Paricalcitol in Reducing Parathyroid Hormone Levels and Ameliorating Markers of Bone Remodelling in Renal Transplant Recipients With Secondary Hyperparathyroidism (NCT01220050) | Mario Negri Institute for Pharmacological Research | 2009-09-01 |
| Vitamin D Deficiency in Chronic Kidney Disease (CKD) Patients (NCT00958451) | Salem Veterans Affairs Medical Center | 2009-07-01 |
| Paricalcitol Oral Therapy in Predialysis CKD Patients. The Greek Experience (NCT01083186) | AbbVie (prior sponsor, Abbott) | 2009-06-01 |
| Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose (NCT00891813) | Abbott | 2009-05-01 |
| Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease Subjects (NCT00888069) | OPKO IP Holdings II, Inc. | 2009-05-01 |
| Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT) (NCT00823303) | Washington University School of Medicine | 2009-02-01 |
| 20070360 Incident Dialysis (NCT00803712) | Amgen | 2009-02-01 |
| Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis Subjects (NCT00664430) | Abbott | 2009-01-01 |
| Study to Evaluate the Effect of Intravenous (IV) Paricalcitol (Zemplar) on Cardiac Morbidity in Patients With Chronic Kidney Disease (CKD) Stage 5 Over 2 Years (NCT01073462) | AbbVie (prior sponsor, Abbott) | 2008-12-01 |
| Comparison of I.V. CTAP201 and Doxercalciferol (Hectorol) in Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (SHPT) (NCT00792857) | OPKO IP Holdings II, Inc. | 2008-11-01 |
| Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease (NCT00742716) | OPKO IP Holdings II, Inc. | 2008-10-01 |
| Efficacy and Safety of Alfacalcidol Compared to Calcitriol for Treatment of Secondary Hyperparathyroidism (NCT01115543) | Mahidol University | 2008-08-01 |
| Long-term Safety Study of Paricalcitol Injection in Chronic Kidney Disease Patients With Hemodialysis (HD) (NCT00701805) | Abbott | 2008-07-01 |
| Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Patients Receiving Hemodialysis (NCT00667576) | Abbott | 2008-04-01 |
| Long-Term Therapy Outcomes When Treating Chronic Kidney Disease (CKD) Patients With Paricalcitol in German and Austrian Clinical Practice (NCT01083849) | AbbVie (prior sponsor, Abbott) | 2008-03-01 |
| Maintenance Vitamin D Therapy for Secondary Hyperparathyroidism (2HPT) (NCT00828347) | Kumamoto University | 2008-01-01 |
| Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis (NCT00537979) | Abbott | 2007-09-01 |
| Treatment of Secondary Hyperparathyroidism in the Uremic Patient (NCT00469599) | Zealand University Hospital | 2007-07-01 |
| A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection (NCT00463021) | Genzyme, a Sanofi Company | 2007-04-01 |
| Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients (NCT00415584) | Montefiore Medical Center | 2007-02-09 |
| A Phase 4 Pharmacokinetic Study of Hectorol Injection and Zemplar Injection in CKD Subjects on Hemodialysis (NCT00454350) | Genzyme, a Sanofi Company | 2007-02-01 |
| Suspected Deficient Activation of Vitamin D in Patients With Secondary Hyperparathyroidism (NCT00754442) | University of Maryland, Baltimore | 2007-02-01 |
| A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis (NCT00418600) | Genzyme, a Sanofi Company | 2006-11-01 |
| ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis (NCT00379899) | Amgen | 2006-09-01 |
| A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With End Stage Renal Disease (ESRD) (NCT00431496) | Amgen | 2006-09-01 |
| E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events (NCT00345839) | Amgen | 2006-08-22 |
| Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis (NCT00446329) | Papageorgiou General Hospital | 2006-07-01 |
| A Study of Zemplar® Injection and Hectorol® Injection on Intestinal Absorption of Calcium in Chronic Kidney Disease (NCT00257920) | Abbott | 2006-06-01 |
| Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease (NCT00261950) | Amgen | 2006-05-01 |
| Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity (NCT00288873) | Weill Medical College of Cornell University | 2006-02-01 |
| Post Transplant Study (NCT00395902) | Amgen | 2005-08-01 |
| ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism (NCT00135304) | Amgen | 2005-08-01 |
| Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism (NCT00123461) | Genzyme, a Sanofi Company | 2005-07-01 |
| Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium (NCT00073710) | Abbott | 2004-09-01 |
| SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism (NCT00117052) | Amgen | 2004-09-01 |
| Bioequivalency Study of Calcitriol Tablets Under Fasting Conditions (NCT00601328) | Roxane Laboratories | 2003-07-01 |
| Study for Secondary Hyperparathyroidism in Chronic Renal Insufficiency Patients (NCT00042432) | Amgen | 2002-06-01 |
| A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Patients on Dialysis (NCT00042653) | Amgen | 2002-05-01 |
| Active Vitamin D Effect on Left Ventricular Hypertrophy (NCT00175149) | Per Ivarsen | 2002-01-01 |
| Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis (NCT00053547) | Abbott | 2002-01-01 |
| A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients (NCT00037635) | Amgen | 2001-12-01 |
| Calcium and Vitamin D Malnutrition in Elderly Women (NCT00352170) | Creighton University | 2000-05-01 |
| Acute Regulation of Parathyroid Hormone by Dietary Phosphate (NCT00037193) | National Center for Research Resources (NCRR) | |